ASX:IMU Imugene (IMU) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Imugene Stock (ASX:IMU) Get Imugene alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume12.70 million shsAverage VolumeN/AMarket CapitalizationA$290.84 millionP/E RatioN/ADividend Yield3.03%Price TargetN/AConsensus RatingN/A Company Overview Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia. Read More Receive IMU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imugene and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMU Stock News HeadlinesImugene (IUGNF) Price Target Increased by 15.52% to 9.81October 1, 2025 | msn.comImugene’s Azer-cel CAR T Therapy Shows Promising Results in Phase 1b TrialSeptember 18, 2025 | msn.comBitcoin grabs headlines, but smart money likes this tokenIf you're a futures trader (or want to be one), this could be the biggest shift you'll ever see in the prop firm world. Even if you have never explored prop trading, now is a great time to get started.October 10 at 2:00 AM | Neuro Street Trading Academy (Ad)Oncolytic Virus Cancer Therapy Market: Epidemiology, Treatments, and Key Companies | DelveInsightSeptember 16, 2025 | theglobeandmail.comOncolytic Virus Cancer Therapy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Oncolys Biopharma, Imugene, Vaxiion ...September 12, 2025 | theglobeandmail.comNSCLC Clinical Trials Assessment 2025: Therapeutics Landscape, FDA Approvals, Pipeline Analysis, Competitive Landscape, Therapies, Medication, ROA, MOA by DelveInsightSeptember 3, 2025 | theglobeandmail.comImugene Expands Market Presence with New Securities QuotationAugust 31, 2025 | tipranks.comImugene Completes Share Purchase Plan, Raising $2.42 MillionAugust 28, 2025 | tipranks.comSee More Headlines IMU Stock Analysis - Frequently Asked Questions How were Imugene's earnings last quarter? Imugene Limited (ASX:IMU) posted its quarterly earnings data on Thursday, February, 28th. The company reported $0.00 earnings per share for the quarter. Imugene had a negative trailing twelve-month return on equity of 95.62% and a negative net margin of 1,855.22%. What other stocks do shareholders of Imugene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Imugene investors own include Meta Platforms (META), NVIDIA (NVDA), Precision BioSciences (DTIL), Fortescue (FMG), Teladoc Health (TDOC), Viralytics (VRACY) and Whitehaven Coal (WHC). Company Calendar Last Earnings2/28/2019Today10/10/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolASX:IMU CIKN/A Webwww.imugene.com Phone61 3 9824 5254FaxN/AEmployees110Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$149.68 million Net Margins-1,855.22% Pretax MarginN/A Return on Equity-95.62% Return on Assets-50.88% Debt Debt-to-Equity Ratio1.31 Current Ratio3.86 Quick Ratio15.17 Sales & Book Value Annual SalesA$4.97 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.75 Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares7,570,000,000Free FloatN/AMarket CapA$290.84 million OptionableNot Optionable Beta3.34 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (ASX:IMU) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenIf you're a futures trader (or want to be one), this could be the biggest shift you'll ever see in the prop fi...Neuro Street Trading Academy | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.For the everyday American who's worked hard to build their nest egg, Trump preserved a IRS loophole that allow...American Hartford Gold | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imugene Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Imugene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
